MYCi361
MYCi361 (NUCC-0196361) is a MYC inhibitor with the Kd of 3.2 μM for binding to MYC. MYCi361 (NUCC-0196361) suppresses tumor growth and enhances anti-PD1 immunotherapy[1].
Product Specifications
CAS Number
2289690-31-7
Product Name Alternative
NUCC-0196361
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
C-Myc
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/myci361.html
Purity
99.95
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
ClC1=CC=C(COC2=CC=C(C3=CC(C(F)(F)F)=NN3C)C(O)=C2C4=CC(C(F)(F)F)=CC(C(F)(F)F)=C4)C=C1
Molecular Formula
C26H16ClF9N2O2
Molecular Weight
594.86
Precautions
H302, H315, H319, H335
References & Citations
[1]Han H, et al. Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. Cancer Cell. 2019 Nov 11;36 (5) :483-497.e15.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Rufy3 sgRNA CRISPR Lentivector (Rat) (Target 1)
Lentiviral human MZF1 sgRNA gene knockout kit - Lentiviral human MZF1 sgRNA gene knockout kit (100)
